ѻý

New Hypogonadism Tx OK'd; Sotagliflozin Nixed for Now

<ѻý class="mpt-content-deck">— News and commentary from the endocrinology world
Last Updated December 3, 2019
MedpageToday

The FDA approved the new oral (testosterone undecanoate) for treating hypogonadism.

In other regulatory news, the agency declined to approve the dual for type 1 diabetes.

The American Diabetes Association released updates to the this week. Changes include the addition of recent cardiovascular trial findings from REDUCE-IT and DECLARE-TIMI as well as chronic kidney disease data.

-- food given only over an 8-hour period -- in postmenopausal mice was tied to slower breast cancer tumor growth compared with mice that had all-day access to food, found a study presented at ENDO 2019. Catch up on all of ѻý's coverage here.

Also out of this year's meeting, the Society released new to be published in May. (Everyday Health)

The American Academy of Pediatrics and the American Heart Association jointly endorsed sugar-sweetened beverage taxes. (ѻý)

Menarche at 16 years or older was tied to a versus women with menarche at age 13. (Neurology)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.